<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01648465</url>
  </required_header>
  <id_info>
    <org_study_id>HE 67/12</org_study_id>
    <secondary_id>2011-006160-48</secondary_id>
    <nct_id>NCT01648465</nct_id>
  </id_info>
  <brief_title>Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors</brief_title>
  <official_title>Phase II Multicenter Single-arm Study Evaluating the Safety and Efficacy of Everolimus as a First-line Treatment in Newly-diagnosed Patients With Advanced GI Neuroendocrine Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hellenic Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the efficacy and safety of everolimus administered as&#xD;
      a first-line treatment in newly-diagnosed patients with advanced or inoperable&#xD;
      Gastrointestinal (GI) or pancreatic neuroendocrine tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">August 6, 2012</start_date>
  <completion_date type="Actual">August 6, 2019</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>15 month PFS (Progression-Free Survival) rate</measure>
    <time_frame>15 months</time_frame>
    <description>To determine the rate of PFS patients at 15 months of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Defined as the time from the date of enrollment to the date of 1st radiologically documented disease progression or disease related death,assessed up to 36 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Defined as the time from the date of enrollment to the date of death from any cause,assessed up to 36 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of best response to treatment and the time to best response achievement</measure>
    <time_frame>Defined as the period from the date of treatment initiation to best response observation date througout the study, assessed up to 15 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of safety</measure>
    <time_frame>Assessment of adverse events will be performed every 28 days (per cycle) during treatment, assessed up to 16 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of biologic markers with disease progression</measure>
    <time_frame>Up to 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Gastrointestinal Tumors</condition>
  <condition>Pancreatic Tumors</condition>
  <condition>Gastrointestinal Neuroendocrine Tumors</condition>
  <condition>Pancreatic Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Everolimus 10mg(2x5mg)orally once daily until disease progression, unacceptable toxicity or consent withdrawal</description>
    <arm_group_label>Everolimus</arm_group_label>
    <other_name>Afinitor</other_name>
    <other_name>RAD001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, aged ≥ 18 years of age.&#xD;
&#xD;
          2. Newly diagnosed patients with biopsy-proven well or moderately differentiated advanced&#xD;
             (metastatic or unresectable) GI or pancreatic neuroendocrine tumor.&#xD;
&#xD;
          3. Measurable disease based on RΕCIST 1.1 using a triphase CT scan or multi-phase MRI&#xD;
             scan.&#xD;
&#xD;
          4. Patients with a ki-67 measurement &lt;20% prior to their enrollment to the study.&#xD;
&#xD;
          5. Performance status 0-2 on the WHO scale.&#xD;
&#xD;
          6. Adequate bone marrow function as shown by:ANC ≥ 1.5 x 10^9/L,Platelets ≥ 100 x&#xD;
             10^9/L,Hemoglobin &gt; 9 g/dL.&#xD;
&#xD;
          7. Adequate liver function as shown by:Serum bilirubin ≤ 1.5 x ULN,ALT/SGPT and AST/SGOT&#xD;
             ≤ 2.5 x ULN (ή ≤ 5 x ULN in patients with known liver metastases),INR &lt; 1.3 (INR &lt; 3&#xD;
             in patients treated with anticoagulants).&#xD;
&#xD;
          8. Adequate renal function as shown by: serum creatinine ≤ 1.5 x ULN.&#xD;
&#xD;
          9. Fasting serum cholesterol ≤ 300 mg/dL or ≤ 7.75 mmol/L and fasting triglycerides ≤ 2.5&#xD;
             x ULN. Note: In case one or both the above upper limits are exceeded, patient&#xD;
             enrollment can only be performed upon proper antilipidemic treatment initiation.&#xD;
&#xD;
         10. Women of childbearing potential, with a negative serum or urine pregnancy test within&#xD;
             48 hours prior to first study treatment administration.&#xD;
&#xD;
         11. Signed informed consent form obtained before any trial related activity, including the&#xD;
             screening phase, according to the applicable law and ICH/GCP requirements.&#xD;
&#xD;
         12. Signed informed consent for the use of biological and genetic material&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with poorly differentiated or undifferentiated GI or pancreatic&#xD;
             neuroendocrine carcinoma.&#xD;
&#xD;
          2. Previous or concurrent cytotoxic chemotherapy, immunotherapy or radiotherapy.&#xD;
&#xD;
          3. Hepatic artery embolization or cryoablation of hepatic metastasis within 1 month of&#xD;
             study enrollment.&#xD;
&#xD;
          4. Prior therapy with mTOR inhibitors (for example sirolimus, temsirolimus, everolimus).&#xD;
&#xD;
          5. Patients receiving chronic treatment with corticosteroid immunosuppressives.&#xD;
&#xD;
          6. Uncontrolled diabetes mellitus as defined by fasting serum glucose &gt; 1.5 x ULN.&#xD;
&#xD;
          7. Patients who have any severe and/or uncontrolled medical conditions such as:&#xD;
&#xD;
               -  unstable angina pectoris, symptomatic congestive heart failure NYHA class II,&#xD;
                  III, IV, myocardial infarction ≤ 6 months prior to enrollment, serious&#xD;
                  uncontrolled cardiac arrhythmia (LVEF &lt; 50 %)&#xD;
&#xD;
               -  active or uncontrolled severe infection&#xD;
&#xD;
               -  cirrhosis, chronic active hepatitis, chronic persistent hepatitis or inadequate&#xD;
                  hepatic function (ALT/SGPT and AST/SGOT &gt; 5 x ULN)&#xD;
&#xD;
               -  inadequate bone marrow (ANC &lt; 1.5 x 10^9/L, platelets &lt; 100 x 10^9/L, hemoglobin&#xD;
                  ≤ 9 g/dL) or renal failure (serum creatinine &gt; 1.5 x ULN&#xD;
&#xD;
               -  severely impaired lung function (patients needing oxygen support).&#xD;
&#xD;
          8. Active bleeding diathesis or on oral treatment with vitamin K antagonists (apart from&#xD;
             low-dose coumadine).&#xD;
&#xD;
          9. Performance status ≥ 3 on the WHO scale.&#xD;
&#xD;
         10. Patients with a known history of HIV seropositivity. Screening for HIV infection at&#xD;
             baseline is not required.&#xD;
&#xD;
         11. No other prior or concurrent malignancy is allowed except for the following:&#xD;
             adequately treated basal cell or squamous cell skin cancer, or treated in situ cancer&#xD;
             of the cervix, or any other cancer from which the patient has been disease free for ≥&#xD;
             3 years.&#xD;
&#xD;
         12. Patients within 28 days post-major surgery (e.g. intra-thoracic, intrabdominal or&#xD;
             intra-pelvic), open biopsy, or significant traumatic injury to avoid wound healing&#xD;
             complications. Minor procedures and percutaneous biopsies or placement of vascular&#xD;
             access device require 7 days prior to study entry. Note: Patients must have recovered&#xD;
             from the acute effects of surgery prior to enrollment.&#xD;
&#xD;
         13. Female patients who are pregnant or nursing (lactating).&#xD;
&#xD;
         14. Adults with reproductive potential who are not using effective birth control methods.&#xD;
             If barrier contraceptive measures are being used, these must be continued throughout&#xD;
             the study by both sexes.&#xD;
&#xD;
         15. Patients participating in another clinical trial or receiving an investigational drug.&#xD;
&#xD;
         16. Patients unwilling or unable to comply with the protocol at the investigator's&#xD;
             discretion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Koumarianou, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>4th Dept of Internal Medicine, University Hospital &quot;Attikon&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>2nd Dept of Internal Medicine, Agios Savvas Cancer Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11522</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Medical Oncology, 251 General Airforce Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11525</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2nd Dept of Internal Medicine, General Hospital of Athens &quot;Hippokratio&quot;</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2nd Dept of Internal Medicine, Propaedeutic, University Hospital &quot;Attikon&quot;</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4th Dept of Internal Medicine, University Hospital &quot;Attiko&quot;</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3rd Dept of Medical Oncology, Agii Anargiri Cancer Hospital</name>
      <address>
        <city>Athens</city>
        <zip>14564</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2nd Dept of Medical Oncology, Metropolitan Hospital</name>
      <address>
        <city>Athens</city>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Medical Oncology, University Hospital of Heraklion</name>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Medical Oncology, Ioannina University Hospital</name>
      <address>
        <city>Ioannina</city>
        <zip>45110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Oncology, Dept of Internal Medicine, University Hospital of Patras</name>
      <address>
        <city>Patra</city>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Medical Oncology, Papageorgiou General Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Medical Oncology, Thermi Clinic</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57001</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 13, 2012</study_first_submitted>
  <study_first_submitted_qc>July 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2012</study_first_posted>
  <last_update_submitted>August 30, 2019</last_update_submitted>
  <last_update_submitted_qc>August 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic</keyword>
  <keyword>unresectable</keyword>
  <keyword>well or moderately differentiated</keyword>
  <keyword>advanced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

